Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "StemPoint Capital"


5 mentions found


Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDepth of weight loss drug pipeline will support growth even as cost lowers, says StemPoint's RossMichelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC's 'Closing Bell' to discuss the criticism Novo has faced around high drug prices, the potential earnings impact if prices come down, and more.
Persons: StemPoint's Ross Michelle Ross, Novo Organizations: StemPoint Capital, Novo Nordisk
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBiotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle RossMichelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.
Persons: Stempoint's Michelle Ross Michelle Ross, Eli Lilly Organizations: Biotech Locations: Stempoint
Chart of the Day: Insmed
  + stars: | 2024-05-28 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailChart of the Day: InsmedMichelle Ross, StemPoint Capital Chief Investment Officer & Managing Parter, joins us with the latest on the stock and a few more biotech names she's watching.
Persons: Insmed Michelle Ross
Hedge fund managers gathered Wednesday at the 2024 Sohn Investment Conference in New York to share their best investment ideas. It kicked off with "Next Wave Sohn," a session that features ideas from rising stars within the hedge fund industry. Endocrinology is an $8 billion market, but the cumulative market size, including the company's future therapy targets, is upward of $200 billion, which includes estimates for future obesity drugs, the investor said. It has CA$75 billion market cap with an "unbelievable record of success," according to the investor. The short seller noted that the company has a $5 billion market cap with about $4.8 billion of debt.
Persons: Sohn, Eric Wolff, Wolff, Michelle Ross, Cushing, Ross, Eli Lilly, Crinetics, XBI, Nikhil Daftary, Alimentation, Daftary, Chris Drose, Nate Koppikar, Fahmi Quadir Organizations: Investment, Gumshoe Capital Management Investment, Pason Systems Energy, Pason Systems, Gumshoe Capital Management, StemPoint, Pharmaceuticals, Crinetics Pharmaceuticals, StemPoint Capital, Endocrinology, Novo Nordisk, P Biotech, NK Capital Investment, NK Capital, Starbucks, McDonalds, Bleecker Street Capital, Orso Partners, Justice Department, Federal Trade Commission, Safkhet, Global Education Locations: New York, Canada, U.S
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailStemPoint's Michelle Ross is bullish on J&J after stronger guidanceMichelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss biotech, weight-loss drugs and her playbook.
Persons: Michelle Ross Organizations: StemPoint Capital
Total: 5